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Abstract This article is an abridged version of the
AWMF mould guideline “Medical clinical diagnos-
tics of indoor mould exposure” presented in April
2016 by the German Society of Hygiene, Environmen-
tal Medicine and Preventive Medicine (Gesellschaft
für Hygiene, Umweltmedizin und Präventivmedizin,
GHUP), in collaboration with the above-mentioned
scientific medical societies, German and Austrian
societies, medical associations and experts. Indoor
mould growth is a potential health risk, even if a
quantitative and/or causal relationship between the
occurrence of individual mould species and health
problems has yet to be established. Apart from al-
lergic bronchopulmonary aspergillosis (ABPA) and
mould-caused mycoses, only sufficient evidence for
an association between moisture/mould damage and
the following health effects has been established:
allergic respiratory disease, asthma (manifestation,
progression and exacerbation), allergic rhinitis, hyper-
sensitivity pneumonitis (extrinsic allergic alveolitis),
and increased likelihood of respiratory infections/
bronchitis. In this context the sensitizing poten-
tial of moulds is obviously low compared to other
environmental allergens. Recent studies show a com-
paratively low sensitizing prevalence of 3–10% in the
general population across Europe. Limited or sus-
pected evidence for an association exist with respect
to mucous membrane irritation and atopic eczema
(manifestation, progression and exacerbation). In-
adequate or insufficient evidence for an associa-
tion exist for chronic obstructive pulmonary disease,
acute idiopathic pulmonary hemorrhage in children,
rheumatism/arthritis, sarcoidosis and cancer. The
risk of infection posed by moulds regularly occurring
indoors is low for healthy persons; most species are
in risk group 1 and a few in risk group 2 (Aspergillus
fumigatus, A. flavus) of the German Biological Agents
Act (Biostoffverordnung). Only moulds that are po-
tentially able to form toxins can be triggers of toxic
reactions. Whether or not toxin formation occurs
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in individual cases is determined by environmental
and growth conditions, above all the substrate. In the
case of indoor moisture/mould damage, everyone can
be affected by odour effects and/or mood disorders.
However, this is not a health hazard. Predisposing
factors for odour effects can include genetic and hor-
monal influences, imprinting, context and adaptation
effects. Predisposing factors for mood disorders may
include environmental concerns, anxiety, condition,
and attribution, as well as various diseases. Risk
groups to be protected particularly with regard to
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an infection risk are persons on immunosuppression
according to the classification of the German Com-
mission for Hospital Hygiene and Infection Prevention
(Kommission für Krankenhaushygiene und Infektion-
sprävention, KRINKO) at the Robert Koch- Institute
(RKI) and persons with cystic fibrosis (mucoviscido-
sis); with regard to an allergic risk, persons with cystic
fibrosis (mucoviscidosis) and patients with bronchial
asthma should be protected.
The rational diagnostics include the medical history,
physical examination, and conventional allergy di-
agnostics including provocation tests if necessary;
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sometimes cellular test systems are indicated. In
the case of mould infections the reader is referred
to the AWMF guideline “Diagnosis and Therapy of
Invasive Aspergillus Infections”. With regard to myco-
toxins, there are currently no useful and validated test
procedures for clinical diagnostics. From a preventive
medicine standpoint it is important that indoormould
infestation in relevant dimension cannot be tolerated
for precautionary reasons. With regard to evaluating
the extent of damage and selecting a remedial pro-
cedure, the reader is referred to the revised version
of the mould guideline issued by the German Federal
Environment Agency (Umweltbundesamt, UBA).
Keywords Mould · Health risk · Indoor · Diagnostics ·
Guideline
Introduction
In April 2016, the German Society of Hygiene, Envi-
ronmental Medicine and Preventive Medicine (Gesell-
schaft für Hygiene, Umweltmedizin und Präventiv-
medizin, GHUP), in collaboration with the above-
mentioned scientific medical societies, German and
Austrian societies, medical associations and experts,
presented the AWMF mould guideline “Medical clini-
cal diagnostics of indoor mould exposure” [1].
This article is an abridged version of this AWMF
guideline. More detailed information on all the con-
tent presented in this abridged version can be found
in the AWMF mould guideline. Whenever reference
is made below to the full version of the guideline,
“AWMF mould guideline” is used.
The core messages of the AWMF mould guideline,
which in turn contain core recommendations, are pre-
sented. The strength of recommendation is expressed
using the following terms: strong recommendation:
“shall”; recommendation: “should”; open recommen-
dation: “may.”
Core messages of the AWMF mould guideline
The problem of indoor mould exposure needs to be
addressed in a more fact-based manner.
1. Relevant levels of indoor mould infestation must
not be tolerated for precautionary reasons. For
the assessment of damage extent, the reader is
referred to the “Guideline on the prevention, in-
vestigation, evaluation and remediation of indoor
mould growth” (mould guideline) issued by the
German Federal Environment Agency (Umwelt-
bundesamt, UBA) [2]. A revised version of the UBA
mould guideline is expected in 2017.
2. The most important measures in indoor mould
exposure include cause identification and appro-
priate remediation (seemould remediation guides
[3, 5]).
3. Medically indicated indoor mould measurements
are rarely helpful. In general, both quantita-
tive and qualitative determinations of the mould
species can be dispensed with in the case of vis-
ible mould infestation. Instead, identifying the
cause of infestation is far more important, fol-
lowed by the elimination of infestation and its
primary causes.
4. Mould exposure can generally lead to mucous
membrane irritation (MMI), odour effects and
mood disorders.
5. Specific clinical pictures seen in mould exposure
are pertinent to allergies and fungal infections
(mycosis).
6. It is the physician’s duty to objectify suspected
links between indoor moisture damage/mould
and gastrointestinal or renal disease, reproduc-
tive disorders, teratogenicity or cancer.
7. Risk groups warranting particular protection in-
clude:
a) individuals on immunosuppression according
to the classification of the German Commission
for Hospital Hygiene and Infection Prevention
(Kommission für Krankenhaushygiene und Infek-
tionsprävention, KRINKO) at the Robert Koch-
Institute (RKI) [11],
b) individuals with cystic fibrosis (mucoviscidosis),
c) individuals with bronchial asthma.
8. The risk for developing asthma (“allergic march”)
is increased in:
a) patients with allergic rhinoconjunctivitis,
b) patients with allergic rhinosinusitis,
c) atopic patients.
9. It is likely that all moulds are capable of causing
sensitization and allergies. Their allergenic po-
tential is considered lower compared with other
environmental allergens [12, 13].
10. As polysensitized individuals, atopics (those sus-
ceptible to hypersensitivity reactions, such as
allergic rhinitis (hay fever), allergic asthma, and
atopic dermatitis on contact with environmen-
tal substances) often also exhibit IgE antibodies
to moulds; however, this does not necessarily
indicate relevant disease.
11. The core elements of allergy diagnostics include
medical history, skin testing (skin prick test), in
vitro serological examination of specific IgE anti-
bodies in type I sensitization or specific IgG an-
tibodies in hypersensitivity pneumonitis (HP; ex-
tremely rare in non-occupationally related indoor
exposure) and provocation testing.
12. The identification of specific IgEmeans that a spe-
cific sensitization to relevant allergens is present.
However, this cannot be equated to a clinically
relevant allergy any more than a positive skin test
reaction can be.
13.Negative in vitro and in vivo tests do not exclude
sensitization or mould allergy.
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14. The determination of specific IgG antibodies as
part of the diagnostic work-up for immediate-type
mould allergy (type I allergy) is of no diagnostic
relevance and is therefore not recommended.
15. Lymphocyte transformation testing (LTT) for
moulds is not indicated as a diagnostic method
[14].
16.Mould-related infections are rare and are most
likely to occur via the inhalative route. In prac-
tice, Aspergillus fumigatus—the most important
mycotic pathogen—is of the greatest relevance
among the 460 moulds classified in risk groups 2
and 3 according the German Technical Rules for
Biological Materials (Technische Regeln für Biolo-
gische Arbeitsstoffe, TRBA). Individuals with local
or general immunodeficiency are by far those
most frequently affected.
17. Core elements of the diagnostic work-up for
mould infection include microbiological, im-
munological, molecular biological and radiologi-
cal methods.
18.Mould-allergic individuals, as well as patients with
diseases that weaken the immune system, should
be provided with specialist patient information on
the hazards of indoor mould exposure and the
preventive steps that can be taken to minimize
this exposure.
Aim of the AWMF mould guideline
The guideline is intended to close the existing gap in
the rational and efficient medical diagnostics of in-
door mould exposure. To date, only guidelines on
building-related procedures in the case of moisture
damage [2–6] and overview articles on associated dis-
eases [7–10] have been available—however, no com-
prehensive, patient-related diagnostic procedure.
The AWMF guideline does not address workplace-
related diseases or specific workplace exposure, oral
ingestion of moulds or mould components or yeast-
and dermatophyte-related diseases.
The scientific literature on moulds is extensive and
largely published in English. In epidemiological stud-
ies, domestic exposure is often categorized using the
terms “dampness and mould,” i. e. no distinction is
made between indoor moisture damage with or with-
out mould infestation. This makes sense, since there
is no health-related marker for quantitative mould
exposure. “Mould” (or “mold” in American English)
refers to “visible” mould structures, whereby “visible”
also includes hidden mould infestation. The terms
“dampness and mould” are translated in the AWMF
mould guideline as “Feuchtigkeit und Schimmel”. Fur-
ther definitions can be found in the appendix to the
AWMF mould guideline [1].
Methodology
A national network of experts belonging to the Ger-
man Society for Hygiene, Environmental Medicine
and Preventive Medicine (Gesellschaft für Hygiene,
Umweltmedizin und Präventivmedizin, GHUP) was
used to compile the AWMF mould guideline. The
guideline builds on the statements of the Robert Koch-
Institute (RKI) Commission ‘Methods and Quality As-
surance in Environmental Medicine’ (Kommission
Methoden undQualitätssicherung in der Umweltmedi-
zin) [8], the World Health Organization (WHO) Guide-
lines for Indoor Air Quality: Dampness and Mould [9]
and the scientific workshops held at the GHUP an-
nual conferences (GHUP 2009–2012) on the subject
of “mould and health” [15–18].
The present guideline has been drawn up in
accordance with the methodological requirements
for the development of diagnostics and treatment
guidelines set out by the German Association of
Scientific Medical Societies (Arbeitsgemeinschaft der
wissenschaftlichen medizinischen Fachgesellschaften,
AWMF) and represents an S2k guideline according to
the AWMF three-level concept. The guideline is based
on an extensive and systematic literature search; how-
ever, it does not formally meet the requirements for
an S2k guideline, since there are no clinical studies
available on this topic. Thus, it was not possible to
assign evidence levels to recommendations.
A search in the Cochrane database with the terms
“mold”, “mould” and/or “dampness” produced three
hits. Two reviews discussed specific immunotherapy
in asthma and rhinitis, while one review analyzed the
preventive effect on respiratory diseases of remediat-
ing damage caused by dampness and mould [19].
A conceptually graduated Medline search yielded
1949 references; screening was subsequently per-
formed for limitation purposes. No reviews com-
prehensively or extensively addressing the topic of
medical diagnostics in exposure to indoor mould and
dampness were found, but rather only literature on
individual topic areas. More details on these can be
found in the AWMF mould guideline [1].
The search was conducted in German using In-
ternet search machines (Google) and in English in
the Medline (Medical Literature Analysis and Retrieval
System Online) database.
Publications by the WHO [9], the Institute of
Medicine (IOM, USA) [7], Palatya and Shum [20]
as well as a recently published review by Mendell
et al. [21] were used to make basic evaluations of
the evidence of a link between mould exposure and
defined clinical pictures.
Other guidelines were considered for individual
topics, primarily diagnostics. These are listed in the
relevant chapters of the AWMF mould guideline [1].
Other guidelines that were consulted include guide-
lines on the following: inhalant mould exposure; al-
lergic rhinoconjunctivitis; rhinitis; rhinosinusitis; di-
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agnostics and treatment of patients with asthma and
bronchial asthma in children and adolescents; asthma
treatment; urticaria; diagnosis of HP; allergic bron-
chopulmonary aspergillosis (ABPA) in cystic fibro-
sis; diagnostics and treatment of invasive Aspergillus
infections; treatment of invasive aspergillosis; diag-
nostics and treatment of invasive fungal infections;
sarcoidosis in childhood and adolescence; manage-
ment of early rheumatoid arthritis; diagnostics and
treatment of adult patients with acute and chronic
cough; in vitro allergy diagnostics; skin testing to
diagnose immediate-type allergic reactions; the per-
formance of nasal provocation tests; the performance
of bronchial provocation tests; workplace-specific in-
halation tests; (allergen-)specific immunotherapy in
IgE-mediated allergic disease; and allergy prevention
(see the AWMF mould guideline for a detailed list [1]).
The procedure used to draw up the guideline is pre-
sented in detail in the AWMF mould guideline [1].
Incidence, exposure and health relevance of
moulds
Definition and increased incidence of moulds
Mould is a collective term for hyphae- and generally
also spore-forming micro-fungi and does not repre-
sent a taxonomically defined fungal entity.
Moulds are a ubiquitous component of our bio-
sphere and are found to varying degrees in outdoor
air, in indoor areas, and in some workplaces.
Mould infestation (of materials) is considered to be
present in building materials and fixtures that have
been, or still are, covered (colonized) by mould. Un-
less already visible to the naked eye, determination
is performed by means of microscopic identification
of a network of hyphae and, by and large, fully de-
veloped conidia- or sporangia-bearers, irrespective of
whether the moulds are still vital/active or have al-
ready died off. Other biomaterial, e. g. bacteria, may
also be present besides moulds.
Mould contamination exceeds the general back-
ground levels of contamination of surfaces or mate-
rials (e. g. with fungal spores) via entry from outside
(e. g. in house dust, airborne spores).
Mould growth refers to a process involving biolog-
ical activity, i. e. it is associated with moisture and
characterized by cell division, hyphae, mycelium and
potentially spore formation, among other things.
Moisture damage is the visible, measurable or per-
ceived effect of increased water content in indoor ar-
eas or structural components.
It makes sense from a practical point of view to
summarize increased indoor exposure to moulds
and other factors associated with increased moisture,
such as yeasts, bacteria (Actinobacteria) and mites, as
moisture/mould damage.
Classification of moulds
Fungi are eukaryotes with cell walls consisting of
chitin and glucans.
The nomenclature of fungi is binomial, i. e. each
organism bears the name of a genus and a species.
However, renaming is relatively common in fungi due
to continuous new findings and taxonomic classifica-
tions. This can lead to communication problems, e. g.
when medical experts specify mould species found
indoors (named differently in the new nomenclature
in the meantime) in their report and include possible
health-related problems in their appraisal. The My-
coBank, an online database, provides current names,
combinations and associated data, e. g. descriptions
and illustrations (http://www.mycobank.org/).
In medical mycology, on the other hand, fungi
are clinically classified into dermatophytes, yeasts
and moulds, irrespective of taxonomy. Although the
DHS system represents a practicable classification,
it is misleading and, from a biological perspective,
(taxonomically) incorrect, since moulds are not a tax-
onomical entity and most “yeasts” (yeast-like fungi)
belong taxonomically to the Ascomycota, as do der-
matophytes.
From a microbiological perspective, moulds should
generally be given taxonomically as genus and species.
If only the Latin genus name is given followed by sp.
or spp., the particular species or group of species have
not been further differentiated.
Another classification with a practical focus is made
according to the different temperature and moisture
requirements of the individual moulds [22, 23].
Mycotoxins
Mycotoxins are secondary metabolites produced by
moulds, which, in low concentrations (µg/kg foods),
can have toxic effects on various cell systems in verte-
brates irrespective of the type of toxin and consump-
tion habits. Numerousmould genera (e. g. Aspergillus,
Penicillium, Fusarium, Alternaria, Stachybotrys) pro-
duce mycotoxins. Mycotoxin production depends on
the species and environmental factors, such as sub-
strate composition, moisture levels, pH value, light
wavelength and nutrient competition [24]. As a gen-
eral rule, mycotoxins produced by indoor-relevant
moulds can be detected in extremely low concen-
trations (parts per trillion, ppt) in house dust [25],
bioaerosols and building materials. Mycotoxins are
not volatile and are found in the air bound to spores,
cell fragments and other particles.
They are generally only found at levels relevant to
health in foods and animal feed that have been colo-
nized by mould.
The hitherto available data indicate that the lev-
els of most airborne mycotoxins found indoors do
not exhibit an acute toxic effect. Only the strongest
toxic compounds, trichothecenes and gliotoxins, may
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be found at their effective concentrations as a result
of mould-infested material indoors [26].
Clearly, the maximum expected levels of individual
mycotoxins in situ (bioaerosols) do not alone explain
these cytotoxic effects. It would appear that the syn-
ergistic effects of various mycotoxins, or mycotoxins
with different cell components (e. g. glucanes, endo-
toxins), are more likely to be responsible for this effect
[8].
It is not yet possible to rule out the possibility that
airborne concentrations of the compounds gliotoxin
in Aspergillus fumigatus (only rarely relevant indoors)
and the satratoxins in Stachybotrys chartarum reach
a level that may be responsible for immunomodula-
tory effects and, thus, potentially promote suscepti-
bility to infection or allergy development [27].
Cell wall components and metabolites
Besides mould spores and mycotoxins, other metabo-
lites and cellular components, such as microbiological
volatile organic compounds (MVOC), β-glucans, man-
nans and ergosterol, also play a role in mould expo-
sure [28, 29], whereby MVOC are responsible for the
characteristic odour of mould.
Ergosterol is a metabolite (sterol) of yeasts, moulds
and edible mushrooms. It is produced as a membrane
component in varying quantities.
Moisture damage is also accompanied by other
microbiological components (e. g. found in house
dust), such as the lysosomal enzyme N-acetyl-ß-D-
glucosaminidase and endotoxin (in bacteria) [30]. It
is not yet known whether these markers (cell frag-
ments, ß-glucan and ergosterol) correlate better with
health effects than do culturable exposure parameters
[31–37].
To date, 77 mould allergens (excluding dermato-
phytes and yeasts) have been described and officially
recognized (www.allergen.org). The associated pro-
tein families differ significantly both biochemically
and structurally from the allergen families in pollen,
foods and animal dander [38].
Health problems and diseases caused by moulds
Epidemiological studies show, consistently and across
studies, a relationship between indoor moisture dam-
age and health effects, in particular: respiratory symp-
toms; eye, nose and throat irritation; blocked nose;
wheezing; dry cough; and fatigue [39]. The AWMF
mould guideline confines itself largely to clinical pic-
tures rather than symptoms.
The relevant evidence of links between moisture/
mould damage and its various health effects is sum-
marized in Table 1. In some cases, it is not possible
to unequivocally establish causality between specific
mould exposure and concrete health-related prob-
lems and clinical pictures.
Table 1 Evidenceofa linkbetween indoormouldexposure
or dampnessanddisorders (excludingmycoses) (modified
from [9, 20, 21, 40, 41])
Causal link
Insufficient evidence
Sufficient evidence for an association:
Allergic airway diseases
Asthma (manifestation, progression, exacerbation)
Allergic rhinitis
Hypersensitivity pneumonitis (extrinsic allergic alveolitis)
Promotion of airway infections, bronchitis
Limited or suspected evidence for an association:
Mucous membrane irritation (MMI)
Atopic eczema (manifestation, progression, exacerbation)
Inadequate or insufficient evidence for an association:
Chronic obstructive pulmonary disease (COPD)




Whether moulds pose a health risk largely depends
on the disposition of the exposed individuals. Risk
groups warranting particular protection include:
a) individuals on immunosuppression according to
the Commission for Hospital Hygiene and Infec-
tion Prevention (Kommission für Krankenhaushy-
giene und Infektionsprävention, KRINKO) [11],
b) individuals with cystic fibrosis (mucoviscidosis),
c) individuals with bronchial asthma.
Ensuring that living conditions meet the highest pos-
sible standards of hygiene should be a fundamental
requirement in all chronic diseases, including those
with no, or insufficient, evidence of a link to mois-
ture damage and/or mould exposure. If hygiene con-
ditions or medical history suggest moisture damage
and/or mould exposure, the primary causes need to
be preventively eliminated, as with all moisture dam-
age [42].
Defined clinical pictures and health disorders
No single mechanism or factor is able to explain the
various health effects related to moisture damage
and/or mould exposure [21, 43, 44]. Epidemiological
findings point to both allergological and non-IgE-me-
diated immunological and toxic, immunomodulatory
mechanisms. Moisture damage or mould growth can
cause adverse effects in atopic as well as non-atopic
individuals [45–48].
The sequence in which diseases are presented in
the following is not intended to indicate any order
of priority in relation to the topics addressed in the
AWMF mould guideline.
1. Allergic rhinitis
As polysensitized individuals, atopics (i. e. persons
with allergic asthma, allergic rhinitis, atopic dermati-
tis) often exhibit IgE antibodies against moulds.
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Depending on the population, region and allergen
spectrum investigated, the incidence of allergic rhini-
tis due to fungal allergens is given at rates ranging
from 2.7–19% [49–51].
IgE-mediated rhinitis is most commonly elicited by
allergens in moulds predominantly found in ambi-
ent air, in particular Alternaria alternata, and signifi-
cantly less frequently Cladosporium herbarum, Botry-
tis cinerea, Mucor sp., Penicillium sp. and Aspergillus
sp. [49–51]. In epidemiological studies, indoor damp-
ness and mould are consistently associated with al-
lergic rhinitis [21, 52]. Monosensitization to indoor
moulds, however, is likely to be rare [53].
2. Non-invasive and invasive sinusitis
Moulds can trigger chronic inflammation of the nasal
and paranasal sinus mucosa via a variety of mech-
anisms [54, 55]. Among sensitizations to moulds in
patients with chronic sinusitis, Alternaria, a typical
mould in outdoor air, is the most prevalent [56].
A distinction is currently made between five forms
of rhinosinusitis triggered by fungi:




d) non-invasive allergic fungal rhinosinusitis (AFRS)
without and
e) with spherical mycetoma formation [54, 57].
The invasive forms are more prevalent in immuno-
compromised patients (AIDS, diabetes, chemotherapy
etc.) and can cause death within a matter of weeks in
the case of an acute (fulminant) course involving vas-
cular invasion by hyphae. The chronic invasive form,
on the other hand, follows a protracted course and,
here again, immunosuppressed patients are predom-
inantly affected. The granulomatous invasive form
represents a type of fibrotic tumour formation, oc-
curring primarily in Africa, Saudi Arabia and the Arab
Gulf States.
Non-invasive AFRS was first described in con-
junction with ABPA [58]. AFRS also resembles this
bronchial disease in many respects. Dematiaceous
hyphae (Bipolaris spicifera, Curvularia lunata) and
Aspergillus species (e. g., Aspergillus fumigatus, A.
niger and A. flavus) are most commonly found to be
the trigger [59].
The presence of a thick, tenacious secretion and the
typical histological finding of abundant eosinophils is
clinically characteristic [60]. In the US, the diagnosis
is considered confirmed if all the major criteria of the
Bent & Kuhn classification are met:
1. Type 1 allergy to fungal allergens confirmed by skin
testing or in vitro testing.
2. Nasal polyposis.
3. Characteristic computed tomography findings.
4. The presence of eosinophilic mucin without inva-
sion.
5. Positive fungal stain of sinus contents removed at
surgery [60, 61].
Recent studies have shown that fungi can be found
in the nose and paranasal sinuses of the vast major-
ity of the population (including all CRS patients) [62].
Thus, alone the presence of fungi does not appear
to be pathognomic—and hence diagnostically signif-
icant—but instead an expression of (a) a reduced im-
mune response in invasive fungal diseases or (b) an
altered, partially excessive immune response in AFRS
to these ubiquitously occurring fungal spores.
Therefore, from a therapeutic perspective, treat-
ment with topical and oral antifungal agents is only
recommended in invasive forms, not however in
AFRS, since double-blind placebo-controlled studies
have not been able to show an effect for these agents
[62], and a pathophysiological relationship to moulds
cannot be assumed in the majority of CRS cases [63].
According to recent findings, severe, untreatable
CRS is caused by (fungal, among other) biofilms. The
precise pathomechanism has not yet been elucidated.
It is likely that planktonic fungi are continually re-
leased by the biofilm; as part of this process, the mu-
cosa is probably invaded by macrophages that phago-
cytose—but do not kill off—the fungal hyphae [64–67].
Fungal biofilms are made up of micro-fungal com-
plexes that are capable of colonizing both biotic and
abiotic surfaces. They cause circumvention of the
immune system and reduce sensitivity to antifungal
agents, while maintaining the ability to release plank-
tonic micro-fungal hyphae. Numerous investigations
using different detection methods have been able to
demonstrate the presence of biofilms in the sinonasal
mucosa of CRS patients [64–67]. The presence of
biofilms was associated with poorer disease courses
[64]. In patients requiring surgery, preoperative dis-
ease severity was greater in a patient group with
proven biofilms in the sinonasal mucosa compared
with a control group in whom no relevant biofilms
were detected; however, the postoperative outcome
was identical in both groups [66].
Confocal scanning laser microscopy with fluores-
cent in situ hybridization was deemed the “gold stan-
dard” in terms of biofilm detection methods [67]. This
method should be combined with other microbiolog-
ical investigations. Traditional culture techniques to
detect and identify pathogens complement this diag-
nostic work-up [67]. Thus, biofilms are an interesting
approach to explaining the persistence of moulds in
the chronically inflamed sinus mucosa. The clinical
significance of biofilms to disease course cannot be
fully assessed as yet. It would be important in the fu-
ture to develop suitable detection methods for routine
clinical application.
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3. Allergic bronchial asthma
As in allergic rhinitis, seasonal allergic bronchial
asthma is primarily induced by moulds occurring
at seasonally high levels in outdoor air (e. g. gener-
ally Alternaria, more rarely Cladosporium, Epicoccum,
Fusarium), whereas indoor moulds (Aspergillus, Peni-
cillium) cause perennial allergic bronchial asthma [8,
68]. The link between damp indoor environments
and/or mould and the development of asthma, par-
ticularly in children, can be considered as undisputed
[21, 69–72].
The outdoormould genus, Alternaria alternata (for-
merly A. tenuis), appears to be a particularly impor-
tant mould in the context of asthma development
and severity [73–77]. A temporal relationship between
asthma symptoms and spore counts was seen partic-
ularly in cases of a high degree of sensitization, as
well as in patients without concomitant grass pollen
allergy. Other authors have emphasized the relevance
in allergic asthma of Cladosporium sp., extremely high
levels of which are found seasonally in outdoor air,
as well as in cases of indoor infestation [78–83]. In
rare cases, patients with seasonal asthma symptoms
(June to September) may exhibit Alternaria sensitiza-
tion without concomitant pollen sensitization [84].
Allergic bronchial asthma is often accompanied
by other atopic diseases (atopic dermatitis, allergic
rhinoconjunctivitis) [8, 85–89]. Monosensitization to
indoor moulds is rare. Clinical investigations show
that, in the case of mould, polyvalent sensitizations to
other environmental allergens are often present [90].
Iversen and Dahl [91] also provide evidence that up
to 95% of mould-allergic asthmatics were additionally
sensitized to other inhalant allergens. The authors
conclude that mould allergens, as weak allergens,
only rarely induce monovalent allergies, or these gen-
erally only occur in patients with a high sensitization
potential, and that genetic predisposition is more
Table 2 Diagnosis criteria for allergicbronchopulmonary
aspergillosis (ABPA) [117, 118, 120] (modified fromRosen-
berg et al. [115])
Diagnostic criteria for allergic bron-
chopulmonary aspergillosis (ABPA)
If not all criteria are met, ABPA
is likely in the presence of the
following minimal criteria:
Specific IgG antibodies (precipitins)
against Aspergillus sp
Asthma




Total IgE (>1000 kU/l) Transient pulmonary infiltrates
Detection of rAsp f 4 and rAsp f 6 Elevated total IgE












relevant in this sensitization process than is mould
exposure in damp homes [91, 92].
4. Atopic dermatitis (atopic eczema)
As airborne allergens, mould allergens can likely trig-
ger atopic dermatitis [86–88]. Epidemiological studies
have yielded sufficient evidence to support a link be-
tween atopic dermatitis and moisture damage/mould
[21].
A variety of dermatological reactions to mould have
been described, such as dryness, pruritus and skin
rashes [93, 94]. Whether this represents an immuno-
logically mediated form of skin reaction to indoor
mould exposure is unclear [44]. However, occupa-
tional contact dermatitis in conjunction with mould
exposure can also be a manifestation of immuno-
logically mediated dermatitis in mould sensitization
[95].
5. Urticaria
In rare cases, the ingestion of foods contaminated
by mould components can trigger urticaria [86, 87].
Examples include mould components (such as en-
zymes) in beverages and bakery products or on dry
fermented sausage/salami [96–98]. Airborne exposure
as trigger of urticaria is unlikely [20] or extremely rare
[99]. Occupational contact urticaria in conjunction
with mould exposure may also be a manifestation of
immunologically mediated dermatitis in mould sen-
sitization [97].
6. Hypersensitivity pneumonitis (HP)
Clinical evidence has documented a link between HP
(synonym: extrinsic allergic alveolitis [EAA]) in sus-
ceptible individuals and the occurrence of mould [7].
With a prevalence of between two and four cases per
100,000 inhabitants/year, HP is a rare allergy (type
III, IV) to inhalant antigens [100, 101]. Indoor mould
plays an important role in this rare disease. The
antigens are found in dust and aerosols; possible mi-
crobially contaminated sources include, for instance,
birds, feathers, hay, wood dust, air humidifiers, air-
conditioning systems, indoor fountains, aquariums
and steam irons [102–104]. Most commonly, the anti-
gens come from birds, moulds and actinomycetes
[105]. Non-smokers are predominantly affected by
HP. Sennekamp [106] has put together a comprehen-
sive antigen catalogue. HP occurs primarily in the
workplace [107] and belongs to the recognized oc-
cupational diseases (OD No. 4201). Non-workplace-
related cases are extremely rare [108–111]. In central
Europe, bird-fancier’s lung is the predominant clinical
picture [106, 112–114].
7. Allergic bronchopulmonary aspergillosis (ABPA)
Allergic bronchopulmonary aspergillosis (ABPA) is
a rare immunological lung disease involving sen-
sitization (IgE and IgG antibodies) to Aspergillus
antigens. It is caused by the inhalation of, and
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colonization by, Aspergillus spores that trigger an
immune reaction. As part of this process, fungi may
grow in the mucus—but not in tissue—and form
hyphae. More rarely, allergic bronchopulmonary my-
coses caused by Helminthosporium, Candida or other
fungi may induce a similar picture. The clinical pre-
sentation of ABPA includes cough, worsening asthma,
hemoptysis and tenacious mucus leading to mucus
plugging. ABPA should be considered if more than
two of the following criteria are met: cystic fibrosis;
bronchial asthma; eosinophilia of unknown etiol-
ogy; volatile antibiotic-resistant infiltrates; acquired
central bronchiectasis; Aspergillus detection in spu-
tum; expectoration of brownish mucus plugs; delayed
cutaneous reaction to Aspergillus. The diagnosis of
ABPA is based on the modified criteria originally pro-
posed by Rosenberg et al. ([115]; Table 2). Recent
investigations show that the combination of elevated
total IgE (>1000 IU/l) and specific IgE against rAsp f 4
and rAsp f 6 permits the diagnosis of classic ABPA
to be made with 100% specificity and 64% sensitiv-
ity. Treatment consists primarily of oral steroids; it is
still not possible to generally recommend antifungal
treatment. There are initial indications that treatment
with omalizumab is able to reduce steroid require-
ments. Since ABPA can cause progressive fibrotic
lung changes if left untreated, early diagnosis and
treatment are important [116–120].
8. Mycoses
Infections caused by environmental fungi are referred
to as exogenous mycoses. The diagnostic work-up
and treatment of mycoses do not form part of the
AWMF mould guideline; instead, only an assessment
is made of the risk of infection upon exposure to in-
door mould, since at-risk patients require individual-
ized medical advice regarding consequences and pre-
ventive measures.
Fungal infections have increased in recent years
[121, 122]. High incidence rates are seen above all in
hemato-oncological patients with long phases of neu-
tropenia, as well as in recipients of allogeneic stem
cell transplantation. However, other forms of im-
munosuppression, such as prolonged corticosteroid
use and interstitial lung disease (including residual
cavitation, e. g. following tuberculosis [123, 124]), as
well as a combination of these factors, especially in
chronic obstructive pulmonary disease (COPD), have
been linked to increased mould infection rates [125,
126]. Thanks to improved treatment options, hema-
tological and oncological patients can now be treated
for longer periods. However, this often leads to longer
periods of increased infection risk, as well as recur-
rent neutropenia. Moreover, there is a trend toward
relocating inpatient chemotherapy to the home envi-
ronment [127]. This can result in increased exposure
in the domestic setting during and/or directly after
chemotherapy. Mould infections are among the most
frequent causes of death due to infectious disease
in hemato-oncological patients, and they are gaining
in significance [121]. Mould-related mycoses in sus-
ceptible patients are usually acquired via the airways.
Primary sites of infection are most commonly the lung
and more rarely the paranasal sinuses, ear or injured
skin. Originating in the respiratory tract, moulds can
spread hematogenously or lymphogenically, thereby
affecting other organs [23].
Although heat-tolerant Aspergillus species are only
rarely found at high levels indoors (potentially in plant
pots), they can be carried into indoor areas, e. g. due
to close proximity to compost or waste treatment fa-
cilities, or as a result of anthropogenic effects (e. g.
agricultural activities).
Individual cases of infection due to opportunis-
tic moulds (mesophilic “environmental” species) have
been described in the literature [128–133]. A recent
analysis of altogether 53 aspergillosis outbreaks af-
fecting 458 patients identified Aspergillus fumigatus
and Aspergillus flavus as the most common species.
Over 50% of affected patients came from hematology/
oncology departments.
In the hospital setting, (nosocomial) mould infec-
tions occur primarily as a result of Aspergillus and
Mucor spore inhalation, contaminated materials, con-
struction work or potted plants. Nosocomial infec-
tions are defined as the diagnosis of an infection >48 h
following inpatient admission. Immunosuppression
generally occurs later, following chemotherapy lasting
for several days. Spore inhalation, on the other hand,
can occur earlier and also prior to inpatient admis-
sion. In this way, spores on the mucosa (e. g. the
paranasal sinuses) may persist and only cause infec-
tion upon immunosuppression. This likely explains
infections that occur even in maximum isolation and
with high-efficiency particulate arrestance (HEPA) air
filtration. As case studies demonstrate, mould in-
fections can also occur outside the hospital setting
[134–138]. The investigations conducted by Chen et al.
[135] in Taiwan on pulmonary fungal infections re-
vealed an increase in community acquired fungal in-
fections. The link between building sites and demoli-
tion works and the resulting increase in fungal spore
exposure in outdoor, as well as (secondarily) indoor,
air is considered as established [139].
With regard to all reports on fungal infections, it
must be borne in mind that it is not unequivocally
clear whether these infections were acquired outside
the hospital setting and/or outside of indoor spaces.
8.1 Invasive aspergillosis. Invasive Aspergillus infec-
tions are an important cause of morbidity and mor-
tality in immunodeficient patients [140, 141]. Insuffi-
cient data is available on the incidence of aspergillo-
sis in Germany; it is associated with high mortality
rates (30–95%) in the over 200,000 annual cases of life-
threatening Aspergillus infection worldwide [142].
The reader is referred to the joint guideline cur-
rently being drawn up by the German-speaking
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Mycological Society (Deutschsprachige Mykologische
Gesellschaft, DMYKG) and the Paul Ehrlich Society
(Paul-Ehrlich-Gesellschaft, PEG) for the diagnosis and
management of (angio-)invasive bronchopulmonary
aspergillosis, as well as to the “Invasive Fungal In-
fection” guideline according to the German Specialist
society for the Diagnostics and Treatment of hemato-
logical and oncological Diseases.
8.2 Aspergilloma. Aspergilloma (mycetoma or fun-
gus ball) is a localized form of aspergillosis that gen-
erally develops in preformed cavities (paranasal sinus,
lungs) due to a build-up of mould mycelia. Predispos-
ing factors include, e. g. caverns secondary to tubercu-
losis, bronchiectasis and malignant disease [143, 144].
9. Organic dust toxic syndrome (ODTS)
Organic dust toxic syndrome is an acute, systemic
flu-like disease caused by the inhalation of high con-
centrations of bioaerosols found almost exclusively in
workplaces. It is significantly more common than HP
(see Section “Toxicological diagnostics”), from which
it is sometimes difficult to distinguish diagnostically
[23, 102, 145]. Table 3 provides a decision-making
aid for the differential diagnosis between HP versus
ODTS. ODTS symptoms have been described in ex-
tremely high bioaerosol exposure. Exposure to high
quantities of dust with an extreme bacterial load (>109
spores/cubic meter, possibly less for Aspergillus fumi-
gatus) [146] can cause asthma and pneumonitis [147],
resembling HP symptoms. Granulomatous scarring
and pulmonary fibrosis may be seen in the case of
continued exposure [146, 148]. Details on the pre-
cise cause of the toxic irritant effect in ODTS are not
known [4, 8].
10. Pulmonary hemorrhage and acute idiopathic
pulmonary hemosiderosis (AIPH)
There is no rationale at present to assume a causal link
between pulmonary hemorrhage and the presence of
indoor mould [149, 150]. Nevertheless, a degree of
association cannot be ruled out [151]. Medical history
taking in children with AIPH should include questions
about dampness/mould [152].
Table 3 Differential diagnosisbetweenhypersensitivity
pneumonitis (HP) andorganicdust toxic syndrome (ODTS)
[8]
CharacteristicsHP ODTS
Exposure Various allergens Endotoxins, high expo-
sure
Incidence 2–30/10,000 10–100/10,000
Latency 4–8 h 4–12 h










Precipitins Often specific IgG Usually negative
11. Susceptibility to infection
There is evidence of a consistent association between
water damage or indoor mould exposure and the de-
velopment of medically diagnosed respiratory tract
diseases (common cold, bronchitis, infections) [21].
Fisk et al. [41] estimate that 8–20% of respiratory
tract infections in the US are associated with mould or
indoor dampness. The link continues to exist even af-
ter controlling for independent variables. Penicillium
sp., Cladosporium sp., zygomycetes and Alternaria sp.
proved to be most closely linked to the development
of these diseases.
The mechanism of this association appears to be
non-allergic in nature [153].
12. Irritant effects—mucous membrane irritation (MMI)
and chronic bronchitis
Besides a variety of environmental factors, dampness
[154] and moulds [155] are associated with mucosal
irritation, referred to as mucous membrane irritation
(MMI)1, and chronic bronchitis [156]. Although the
pathophysiological links between exposure to these
environmental factors and MMI or chronic bronchi-
tis have not been elucidated as yet, the mucosal ep-
ithelium and local neurons have been attributed with
a key role in MMI [157]. According to a Danish study,
long-term exposure to damp indoor spaces causes
mucosal hyperreactivity in nasal histamine provoca-
tion that persists even after remediation [158].
The prevalence of mucosal irritation among indi-
viduals occupationally or environmentally exposed to
bioaerosols is put at approximately 20–30% [159–161].
There are no reliable data as yet—in general or specif-
ically for indoor mould exposure—on the prevalence
of these non-allergic, irritant, inflammatory effects.
Possible irritant symptoms in MMI include non-
specific irritation of the mucous membrane of the eye
(e. g. burning, watering, itching), the nose (e. g. sneez-
ing, secretion and obstruction of the nasal cavity) and
the throat (e. g. feeling of dryness, clearing of the
throat). In addition, irritant inflammatory processes
in the deeper airways (e. g. cough) may manifest as
chronic bronchitis [156]. Symptoms seen during ex-
posure, such as coughing, burning, itching of the eyes
and nose and skin irritation, resolve rapidly once ex-
posure ceases. From a differential diagnostic perspec-
tive, it is important to distinguish allergic symptoms
that, unlike irritant reactions, generally increase upon
repeated and long-term exposure due to sensitization
[162]. The irritant toxic effects of moulds can possibly
be attributed to metabolites or cell wall components
(glucans), as well as to a reaction to the release of in-
terleukins or other inflammatory mediators [39]. As
part of this, synergistic effects of various mycotoxins
and/or mycotoxins with other microbiological agents
1 Sometimes also referred to as mucous membrane irritation
syndrome (MMIS).
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(e. g. glucans, endotoxins from bacteria) may be re-
sponsible for this effect [32, 34, 163–165].
13. Sarcoidosis and moulds
In sum, there is only unreliable evidence that differ-
ent forms of microbial inhalation exposure, including
water damage, can increase the risk of developing sar-
coidosis; no causal link between mould exposure and
sarcoidosis has been established as yet [166, 167].
Thus, in future studies on the etiology of sar-
coidosis, it would make sense to pose questions
regarding inhalant—including infectiological—factors
and water damage in patients’ domestic and occu-
pational environments during medical history taking
[168–173]. However, there is currently insufficient
data to assume a causal link between the develop-
ment or exacerbation of sarcoidosis and water damage
or mould exposure.
No specific mould-related diagnostic work-up is in-
dicated in sarcoidosis above and beyond the usual
procedure.
14. Rheumatic disorders
Infections (bacterial, viral) have long been discussed
as triggering factors in numerous inflammatory rheu-
matic diseases. A working group has produced
evidence of a link between moisture damage and
rheumatic disorders [174–177]. The occurrence of
a cluster in one building was attributed to the pres-
ence of moisture damage and “abnormal” microbial
exposure [175].
However, until studies from other centres (and
countries) are available, one cannot assume that the
current evidence is sufficiently robust. Given that
the epidemiological evidence is insufficient, it is not
possible to make any statements on incidence or
any possible links between mould exposure and/or
moisture and rheumatic disease.
No specific mould-related diagnostic work-up is
indicated in rheumatic disorders (interdisciplinary
guideline, management of early rheumatoid arthritis)
above and beyond the usual procedure.
15. Mycotoxicosis
Systemic effects (poisoning) caused due to the myco-
toxins produced by moulds are referred to as myco-
toxicosis and are known to occur upon oral ingestion
of contaminated foods [105].
There is no reliable knowledge to date of indoor
airborne mycotoxin poisoning. It also remains to be
established whether mycotoxin levels in indoor air are
relevant in terms of a systemic toxicological risk. Ac-
cording to the findings available to date, this does not
appear to be the case.
16. Odour effects
Mould metabolites can cause relevant odours to be
perceived [178]. This should prompt a structural in-
vestigation into the cause of indoor moisture/mould
damage.
The term microbial volatile organic compounds
(MVOC) refers to volatile organic compounds pro-
duced by moulds and bacteria [178–180]. It is impor-
tant to bear in mind that there are also other sources
of MVOC besides microbial sources (tobacco smoke,
cooking, baking, roasting, pot plant soil, compost bin
etc.) [181]. It has not yet been elucidated whether
biological signalling effects come from MVOC at the
low µg/m3-range levels found indoors [182]. Olfac-
tory–psychological coupling reactions with nonspe-
cific symptoms are possible in the case of cacosmia-
related abnormalities; toxic reactions, on the other
hand, are unlikely [183, 184].
Environmental odours can affect health and well-
being in various ways. A distinction needs to be made
between: direct physiological effects; odour percep-
tion; odour pollution as an effect of the odour on an
emotional level; and indirect physiological effects due
to odour pollution and the resulting chronic stress.
In the reality of environmental health analysis, it is
not always possible to distinguish between the health
effects caused by odours via the above-mentioned
mechanisms.
The characteristic effect of unpleasant odours is
that they pose a nuisance. Although mood disorders
as a health effect are possible, these are not mediated
via toxicological mechanisms, but rather via condi-
tioning, attribution (of links), or stress. Mood disor-
ders can be understood as precursors to somatic dys-
function. Typical symptoms due to highly unpleasant
odour pollution can include fatigue, lack of concen-
tration, nausea, headache and insomnia [185].
The perception and cognitive appraisal of—and
thus also sensitivity to—odours are subject to con-
siderable inter-individual variability. Genetic and
hormonal factors, as well as character, context and
adaptation effects, play a role here [186].
17. Mood disorders and nonspecific symptoms
Mood disorders are defined as “a deterioration in psy-
chological, physical, and social well-being and feel-
ing of subjective performance capacity. As an emo-
tional experience, they need to be distinguished from
stress responses, which include a cognitive evaluation
of specific environmental stimuli” [187, 188]. Mood
disorders play a crucial role in environmental health
disorders in general, as well as in health disorders
related to indoor environments in particular [189].
Three models are used to explain the mode of action
of these types of environment-relatedmood disorders:
the noxious agent model, the attribution model and
the stress model [187, 188]. It is possible in princi-
ple that environment-relatedmood disorders could be
triggered by moulds, e. g. as a result of odours [189].
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Table 4 Riskgroupsamong immunosuppressed individuals according to theCommission forHospital Hygieneand Infection
Prevention (Kommission für Krankenhaushygiene und Infektionsprävention, KRINKO)at theRobertKoch-Institute [11]
Risk group 1 (moderate immunosuppression/-deficiency)
– Granulocytopenia <0.5 × 109/l (< 500/μl) for up to 10 days (similarly, leukopenia <1 × 109/l; < 1000/μl)
– Deficiency of CD4-positive T-helper cells <250/μl (note: age-appropriate normal values in children); autologous stem cell transplantation up to 3 months
following intensive treatment phase
Patients exhibiting more than one feature of immunosuppression/-deficiency listed in risk group 1 come under risk group 2
Risk group 2 (severe immunosuppression/-deficiency)
– Granulocytopenia <0.5 × 109/l (< 500/μl) for more than 10 days (similarly, leukopenia <1 × 109/l; < 1000/μl)
– Severe aplastic anaemia or macrophage activation syndrome under intensive immunosuppressive treatment
– Allogeneic bone marrow or stem cell transplantation up to 6 months following completion of intensive treatment (important: degree of the graft-versus-host
disease (GVHD) and continued iatrogenic immunosuppression)
– Acute inpatient treatment phase in autologous stem cell transplantation or following solid organ transplantation (up to hospital discharge)
Risk group 3 (very severe immunosuppression/-deficiency)
– Allogeneic bone marrow transplantation/allogeneic blood stem cell transplantation (PBSCT) in the intensive treatment phase (until engraftment = regenera-
tion of granulopoiesis)
– Severe grade III or IV GVHD under intensive immunosuppression
The decision on whether to assign allogeneic stem cell transplantation patients to group 3 is ultimately taken by considering an overview of all findings from the
treating oncologists
18. Neuropsychological and neurotoxic effects
The specialist literature does not point to a consistent
causal relationship between indoor toxin levels and
neurotoxic effects [43, 190–193]. Evidence of a link is
insufficient [194].
19. Gastrointestinal effects, renal effects,
teratogenicity and cancer
To date, there have been no systematic investigations
or case descriptions that provide evidence of, or sug-
gest an association between, indoor moisture damage
or mould and gastrointestinal or renal disease, repro-
ductive disorders, teratogenicity or cancer (see [20,
150]).
It is the physician’s duty to investigate a possible
causal link in such cases.
Risk analysis and assessment
Risk of infection
The risk of infection from common indoor mould
species is low in healthy individuals; most species
are classified in risk group 1 and only a handful in
risk group 2 (Aspergillus fumigatus, A. flavus) of the
German Biological Agents Act [195].
The current German Biological Agents Act, which
regulates occupational tasks involving (the handling
of) moulds, classifies the risk of infection from bio-
logical agents at the workplace into four risk groups
[196], whereby moulds fall into risk groups 1 and 2:
● Risk group 1: Biological agents that are unlikely to
cause human disease.
● Risk group 2: Biological agents that can cause hu-
man disease and might pose a hazard to workers;
it is unlikely to spread to the community; effective
prophylaxis or treatment is usually available.
● Risk group 3: Biological agents that can cause severe
human disease and pose a serious hazard to work-
ers; there may be a risk of spreading to the commu-
nity, but effective prophylaxis or treatment is usually
available.
● Risk group 4: Biological agents that can cause severe
human disease and pose a serious hazard to work-
ers; theremay be a high risk of spreading to the com-
munity; effective prophylaxis or treatment are usu-
ally not available (risk group 4 does not include any
fungi).
Mould mycoses are opportunistic infections. They re-
quire exposed individuals to have reduced immune
status. Heat-tolerant mould species in risk group 2
(e. g. A. fumigatus, A. terreus, A. niger, A. flavus, Emeri-
cella nidulans and mesophilic Fusarium sp.) of the
classification of moulds into risk groups according to
the Technical Rules on Biological Agents (TRBA 460)
[195] in the German Biological Agents Act [196] only
rarely cause infections in healthy, immunocompetent
individuals; however, they can trigger mycosis in in-
dividuals whose immune system is incompetent due
to disease or other factors [197, 198].
According to KRINKO at the Robert Koch-Institute
[11], immunosuppressed individuals can be classi-
fied into three risk groups (Table 4). Patients at
particular risk include (in descending order of risk):
cancer patients, in particular those with underly-
ing hemato-oncological disorders (e. g. leukaemia,
lymphoma), acute myeloid leukaemia (AML), acute
lymphatic laeukemia (ALL), allogeneic stem cell trans-
plantation, autologous stem cell transplantation, solid
organ transplantation, HIV infection, other forms of
immunosuppression (e.g. a long-term high-dose
treatment with glucocorticoids), aplastic anaemia
and cystic fibrosis, among many others [121, 199].
AML is associated with the highest incidence of in-
vasive mould infections (around 12%) and the most
mould infections (around 8%). This is followed by
ALL at around 4%. Among the procedures, allogeneic
hematopoietic stem cell transplantation (allo-HSCT)
is associated with an extremely high incidence of
mould infections [121].
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Due to the continuously rising proportion of im-
munosuppressed patients in the population and the
ever longer survival rates among this patient group,
it is not possible at present to exclude the possibility
that mould infections may become a growing health
risk factor in this population group [8].
It is not possible to calculate a numerical risk on
the basis of current knowledge. Risk matrix 1 (Fig. 1)
shows a semiquantitative risk assessment of the risk
of infection due to indoor moulds.
Risk of sensitization/allergy
In principle, there is a possibility of sensitization
and the triggering of a clinically symptomatic allergy
also among healthy individuals following inhalation of
spores and other mould components (e. g. mycelium).
The sensitizing potential of moulds is considered sig-
nificantly lower [177, 202–204] compared with aller-
gens from, e. g. fur-bearing pets, grass and tree pollen
or house dust mites [200, 201]. Recent population-
and patient-based [13] studies reveal a compara-
tively low prevalence of sensitization across Europe of
3–10% measured relative to the total population [12].
It can be said as a general rule that sensitization—also
to moulds—is not equivalent to a clinically relevant
allergy. It is generally assumed that there are over one
million mould species. Around 350 mould species
have been listed on www.allergome.org as potentially
sensitizing. However, it is not possible to infer how
high the total percentage of sensitizing moulds is on
the basis of this information. At present, 107 mould
proteins from 43 mould species fulfil the WHO/IUIS
criteria for classification as an allergen (www.allergen.
org). Only a handful of moulds are available as test
allergen solutions and typical indoor fungal allergen
extracts are largely lacking [38, 205].
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From an allergological perspective, an exposure
dose-dependence (measured as colony forming units,
CFU) does not alone determine the clinical reaction
in mould-sensitized patients. Sensitization with the
formation of specific IgE antibodies and the trigger-
ing of allergic reactions takes place on the protein
or peptide-component level. Thus, it is not neces-
sary for whole spores or intact mould mycelium to
be present. Allergenicity depends far more on the
proteins or peptides which, due to their properties,
are allergy-triggering.2
Exposure to damp indoor spaces represents a risk
factor for developing bronchial asthma in individuals
with atopy, rhinoconjunctivitis and rhinosinusitis. In
the case of rhinosinusitis associated with mould expo-
sure, the risk for developing bronchial asthma doubles
(Odds ratio [OR]: 2.2; confidence interval [CI]: 1.3–3.6)
[206]. Young atopic children appear to be at higher
risk for developing bronchial asthma in the case of
moisture damage or mould exposure in the bedroom
or living room [207].
It is not possible to calculate a numerical risk value
on the basis of current knowledge. Risk matrix 2
(Fig. 2) shows a semiquantitative risk assessment of
the risk of sensitization/allergy due to indoor moulds.
Risk of toxic/irritative effects
Only those moulds that are potentially able to form
toxins come into consideration as triggers of intoxi-
cation. Whether indoor toxin formation takes place
in individual cases depends on environmental and
growth conditions and, in this regard, most notably
on the substrate [150, 208].
No predisposing factors for mycotoxin intoxication
in humans are known. However, predisposition on
a target-organ level is conceivable. For example, it is
imaginable that pre-existing liver disease (e. g. chronic
hepatitis, liver cirrhosis) could represent a predispo-
sition for the hepatotoxic effects of aflatoxin following
oral ingestion of this toxin. Whether this also applies
to airborne toxin intake remains hitherto unclear [8].
It is not possible to calculate a numerical risk on
the basis of current knowledge [43].
It is unclear to date whether persons affected by
MMI or chronic bronchitis are particularly sensitive
individuals and react even to small doses, or whether
sensitized individuals react differently, independent of
dose, compared with non-sensitized individuals [157].
Other inflammatory processes in the area of the mu-
2 Definition of the term “allergen”: Allergens are antigens which
cause allergy. Most allergens reacting with IgE and IgG antibody
are proteins, often with carbohydrate side chains, but in certain
circumstances pure carbohydrates have been postulated to be
allergens. In rare instances, low molecular weight chemicals,
e.g. isocyanates and anhydrides acting as haptens, are still re-
ferred to as allergens for IgE antibodies (WAO/EAACI Allergy
Definitions, http://www.worldallergy.org/professional/allergic_
diseases_center/nomenclature/english.php).
cosa of the eyes and respiratory tract, such as infec-
tions, atopic mucosal disorders, keratoconjunctivitis
sicca and dry nasal mucosa, can be possible predis-
posing factors for MMI and chronic bronchitis [8].
Risk of odour effects and mood disorders
In principle, odour effects and/or mood disorders
as a result of indoor moisture/mould damage can
affect anyone. This does not represent a health risk.
Predisposing factors for odour effects may include
genetic and hormonal influences, character, context,
and adaptation effects [186].
Predisposing factors for mood disorders may be en-
vironmental concerns, fears, conditioning, and attri-
butions, as well as numerous diseases [209].
Diagnostic work-up
Reason for seeking medical advice
Patients generally seek medical advice in conjunction
with mould exposure for the following reasons [105,
162]:
1. Patients experience health problems, the circum-
stances of which suggest an environment-related
link to moisture damage and/or mould exposure.
2. Patients have mood disorders and nonspecific
symptoms that are in clear temporal relationship
to certain environmental/ambient conditions or
activities.
3. Patients are concerned about possible mould expo-
sure.
4. Measurements are already available.
5. Medical support is sought in rental and construc-
tion disputes.
Diagnostic work-up: general procedure, medical
history, physical examination and clinical chemical
and instrument-based tests
Medical history [210] and physical examination are
the basic elements of any medical diagnostic work-
up. On the basis of these, further special investiga-
tions are performed within the relevant medical spe-
cialty depending on the diagnostic question and dif-
ferential diagnostics. In addition, in environmental
and occupational medicine, investigations to internal
exposure (human biomonitoring in the form of expo-
sure and/or effect monitoring) and/or external expo-
sure (home/site visit, environmental monitoring) are
always performed if possible and where indicated.
Medical history
Medical history taking should involve a holistic ap-
proach that is not confined to environmental exposure
and aspects of physical disease alone, but one that
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also takes the psychosocial dimension equally into ac-
count. This approach, which is particularly necessary
in view of the patient’s high expectations of the physi-
cian, should be explained to the patient. Giving equal
priority to psychological and social aspects rarely pro-
duces difficulties in the consultation setting once the
approach has been explained to the patient.
In addition to the general and differential diagnos-
tic history, the following elements should be consid-
ered during medical history taking in the case of sus-
pected health disorders due to mould:
● history of exposure in the home,
● history of exposure in the workplace,
● history of exposure during leisure time,
● history of infections, including predisposing factors,
● history of allergies, including predisposing factors,
● history regarding irritant toxic effects,
● history regarding odour effects,
● history regarding mood disorders.
Physical examination
A complete, or at least symptom-oriented, physical
examination always forms an integral part of medical
history taking. The method of physical examination
is based on inspection, palpation, percussion, auscul-
tation and functional testing.
The target organs noted in the medical history
should take priority in the examination. Particular at-
tention should be paid to the mucosa of the eyes and,
as far as possible, upper airways, as well as to the
skin, since the nonspecific symptoms that patients
often complain of relate to these organs in particular
[22, 211]. As a basic rule, the physical examination
should be performed in a structured and standard-
ized manner and should be adequately documented.
A variety of clinical finding forms are available to this
end.
Markers of mould exposure
Environmental monitoring
As a rule, there is no medical indication to determine
mould indoors, in building materials or on fixtures.
From a medical perspective, a visual inspection
of mould infestation is sufficient to initiate medi-
cally justified measures. The greatest relevance is
attributed to site visits, which are ideally performed
by a physician and experts with structural expertise.
In the case of visible mould infestation, increased
moisture levels in materials or structural abnormal-
ities (moisture or water damage), the identification
and quantification of indoor mould is not indicated
from a diagnostic and therapeutic perspective [212].
The differential diagnosis always takes priority
when assessing the health effects of mould expo-
sure. Since the effect of mould depends primarily
on the disposition of the affected individual, any de-
lay caused through mould determination in taking
steps may put persons requiring particular protection
from mould at increased risk. Risk groups warranting
particular protection include:
● immunosuppressed individuals according to the
three risk groups defined by the KRINKO at the
Robert Koch-Institute [11],
● individuals with cystic fibrosis (mucoviscidosis),
● individuals with bronchial asthma.
In the above-mentioned patient groups, tests on the
basis of relevant suspicion are seldom medically indi-
cated to assess risk purely for preventive purposes.
Gabrio et al. (2015) recently presented a summary
of test methods available to ascertain mould expo-
sure in indoor mould infestation, e. g. due to moisture
damage [213]. Their summary is designed to provide
not only treating physicians, but also environmental
mycologists, indoor diagnosticians, craftsmen, archi-
tects and building experts responsible for ordering
or evaluating measurements, with sound knowledge
about useful (or redundant) applications and the re-
liability of the various measuring and test methods,
thereby making a solid basis available for the commis-
sioning or assessment of relevant tests. The reader is
referred to the pertinent literature for a more in-depth
discussion of this topic [2, 4, 214, 215].
Clinical diagnostics
1. Allergy diagnostic work-up
The diagnostic work-up here does not differ from that
in other allergic diseases. A stepwise approach is taken
that considers individual factors according to the clas-
sic step-by-step model: medical history/physical find-
ings/clinical investigation—skin tests—serum analy-
sis or complementary in vitro methods—provocation
[89, 216].
Allergic disorders due to mould allergens can es-
sentially manifest as conjunctivitis, rhinitis, rhinosi-
nusitis, allergic bronchial asthma, urticaria, HP and
ABPA. As a result, the differential diagnosis based on
medical history and clinical laboratory in vitro/in vivo
testing is of central importance. In individual cases,
the allergic reaction needs to be confirmed and the
allergy trigger identified. There is a wide variety of in
vitro tests to measure parameters of the cellular and
humoral allergic reaction on different levels. How-
ever, the repertoire of commercially available mould
allergen extracts is limited and primarily covers typi-
cal species found in outdoor air.
Particularly in in vitro testing, it is important to
bear in mind that increased mould-specific IgE lev-
els, for instance, can indicate sensitization to mould
allergens, but do not equate to allergic disease. A cor-
rect interpretation of results is only ever possible in
conjunction with the medical history, clinical picture
and/or the results of organ-specific provocation tests.
Given the possibilities for exposure (ubiquitous out-
door exposure, indoor exposure and occupational ex-
posure), evidence of positive sensitization to mould
needs to be regarded critically in the assessment of
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causality. It is extremely rare in routine allergology/
environmental medicine for a causal link to be reli-
ably confirmed between indoor mould exposure and
an associated specific sensitization and disease (rhini-
tis, conjunctivitis, asthma) [8].
The following conditions need to be met in order
for a mould allergy to be diagnosed [217]:
● A pathogenic mould antigen is present in the envi-
ronment.
● There is an unequivocal temporal relationship be-
tweenallergic symptoms and exposure to themould
allergen.
● Atopic predisposition is present.
● There is evidence of specific IgE formation tomould
antigens.
● Measures to avoid mould allergens exhibit clear
clinical effects.
In principle, the same recommendations and guide-
lines apply to the diagnostics of mould allergy as to
other allergen sources that cause immediate-type al-
lergies [218].
1.1 Serological investigations. Serological in vitro
tests include specific IgE antibody determination in
the case of IgE-mediated disease, or specific IgG an-
tibody determination in the case of HP. Although the
identification of elevated specific antibodies is a clear
indication of sensitization, this does not equate to
clinical relevance; having said that, the predictive
value for clinical relevance increases according the
degree of sensitization [219].
1.2 Identification of mould-specific IgE antibodies.
The identification of allergen-specific IgE indicates
specific sensitization, but not necessarily disease; re-
sults can only be correctly interpreted in conjunction
with medical history, clinic picture and the results of
organ-specific provocation tests. Positive reactions
caused by cross-sensitivity are of only partial clinical
relevance.
A quantitative comparison of results from different
test systems is challenging (call for international stan-
dards).
A call needs to be made for the improvement of
reagent quality by standardizing the allergens and
defining minimum requirements for the allergen-
carrier material (determining diagnostic efficacy).
Extracts of indoor-relevant moulds should also be
commercially available in adequate quality.
The spectrum of available single allergens from the
relevant moulds needs to be expanded.
1.3 Mould-specific IgG determination. Only in the
case of suspected ABPA (type I and III allergy) or HP
(type III and IV allergy) can mould-specific IgG an-
tibody determination make a helpful contribution to
diagnosis and, as such, be recommended [101, 107].
In ABPA, a significant increase is seen not only in
total IgE and specific IgE against A. fumigatus (see
above), but also in specific IgG against A. fumiga-
tus. The latter is markedly elevated compared with
patients allergically sensitized to A. fumigatus and is
therefore recommended in the differential diagnosis
of ABPA.
1.4 Cytokines and eosinophil cationic protein (ECP).
There is no special indication for these nonspecific
markers of eosinophil activation and recruitment in
the identification of mould allergy.
1.5 Immune complex analysis. The analysis of im-
mune complexes is confined to particular disorders
in the realm of type III allergic reactions, such as HP,
and has no place in the diagnostics of mould expo-
sure beyond this (see mould-specific IgG determina-
tion above).
1.6 Galactomannan in serum. The detection of
serum galactomannan for diagnostic purposes is only
indicated in invasive aspergillosis [220].
1.7 β-1,3-D-glucan in serum. The detection of
(1→3)-ß-D-glucan in serum is technically challenging
and could be helpful in the diagnostic work-up of
invasive mycosis. Its application is not indicated in
conjunction with indoor mould [221].
1.8. Mycotoxins in serum. Current analytical possi-
bilities do not permit the reliable determination or
evaluation of indoor mycotoxin exposure. The deter-
mination of mycotoxins in blood, serum or urine is of
no relevance in practical medicine and must remain
confined to scientific investigations for the time being.
2. Cellular assays
Rare indications for tests with the “basophil granulo-
cyte” target cell include samples with extremely low
total IgE and failed specific serological IgE detection
in the case of suspected sensitization or exotic aller-
gens.
2.1 The basophil degranulation test and histamine
release. The histamine release test (HRT) is not
helpful in the diagnostics of mould allergy.
2.2 The basophil activation test by flow cytometry
(Flow CAST). This test is beneficial in the case of
inhalant allergens, particularly when skin testing and
specific IgE measurements are not possible. Rare
indications include samples with low total IgE, failed
serological specific IgE detection and possibly neg-
ative skin tests in suspected sensitization or exotic
allergens.
2.3 Determination of other effector-cell mediators
(leukotriene release test, cellular antigen stimula-
tion test [CAST]). Testing positive to an allergen,
which represents an indirect identification of sensiti-
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zation, is only indicative of a clinically relevant allergy
in conjunction with a positive medical history and/or
positive provocation tests. This test is also complex
to perform and not suited to routine diagnostics.
2.4 Lymphocyte transformation test. Since mould
allergens do not cause type IV sensitization, lympho-
cyte transformation testing for mould is not indicated
as a diagnostic method [14].
3. Provocation tests
In cases where medical history, physical examination
and serology fail to unequivocally establish the diag-
nosis of a mould allergy, provocation testing may be
indicated if this will significantly impact treatment,
prevention and/or compensation [222]. Organ-spe-
cific provocation testing is aimed at confirming the
clinical relevance of existing sensitizations or suppos-
edly observed symptoms.
At present, only a few commercial mould allergen
test extracts are available from a handful of manufac-
turers. As shown in investigations published by Ke-
spohl et al. [223] in 2013 using detailed biochemical
and immunological analysis, mould allergen extracts
exhibit high variability in terms of allergen compo-
sition, and preparations of a fungal species are not
comparable between different manufacturers. Skin
test extracts of the outdoor mould Alternaria are an
exception here.
3.1 Skin testing. After medical history, skin tests (ST)
form the basis of the allergy diagnostic work-up and
are fast and relatively cost-effective to perform. As
a general rule, they are sufficiently meaningful and are
associated with a low complication rate. ST should
be performed according to the relevant German or
European position papers [224].
A distinction is made in skin testing between epi-
cutaneous (patch, friction) and cutaneous (scratch,
skin prick and intracutaneous) tests. The allergen
concentration in solutions used for intracutaneous
testing is usually 100- to 1000-fold lower compared
with skin prick test solutions. However, since intra-
cutaneous test solutions have not been commercially
available since June 2015, this diagnostic method to
detect mould sensitization no longer applies.
3.2 Nasal provocation testing. The nasal provoca-
tion test (NPT) makes it possible to reproduce an
allergic reaction at the manifesting organ under stan-
dardized conditions and is considered a simple and
safe method with high specificity and sensitivity
[224–227]. It is recommended that tests be per-
formed and evaluated according to standards set out
in the German Society for Allergology and Clinical Im-
munology (Deutsche Gesellschaft für Allergologie und
klinische Immunologie, DGAKI) guideline [228].
Inhalation allergies tomould spores generally cause
persistent respiratory tract symptoms; this can make
it challenging to establish an unequivocal relationship
to the medical history. In this context, NPT is able to
confirm or exclude a suspected diagnosis of an aller-
gic reaction of the respiratory tract. NPT is also in-
dicated in cases where skin testing is contraindicated
or local allergic rhinitis is suspected, and to monitor
the course of treatments such as allergen specific im-
munotherapy (SIT).
3.3 Conjunctival provocation testing. The conjunc-
tival provocation test (CPT) should only be performed
when the patient is free of symptoms; standard-
ized skin prick test solutions (1:10 dilution, possibly
higher) are generally used [229].
A CPT may be indicated if
● symptoms are predominantly conjunctival,
● an NPT for nasal symptoms is not possible due to
contraindications or recent endonasal surgery.
3.4Bronchial provocation testing. A bronchial prov-
ocation test (BPT) may be indicated if it is not possible
to establish the diagnosis on the basis of a combi-
nation of exposure tests and less invasive diagnostic
tools, such as medical history and skin testing. Med-
ical history is generally not helpful, particularly in
perennially occurring indoor moulds. Optionally,
there is an indication to confirm diagnosis prior to
hyposensitization, as well as in cases where a court-
admissible expert opinion on a link to a particular
instance of exposure is required [222]. As with other
inhalant allergens, the degree of sensitization can
be taken into account as a guide. As such, the BPT
plays an important role in suspected allergic peren-
nial asthma due to indoor moulds. Allergen selection
should be guided by the spectrum of sensitization.
The evidence for provocation testing in the event of
failure to detect sensitization is insufficient, meaning
that no recommendation can be made in this re-
gard. The spectrum of commercial extracts available
for provocation testing is progressively narrowing.
The test must be performed according to the relevant
guidelines. When assessing allergen provocation tests,
one should expect false-positive as well as false-neg-
ative reactions. It is generally problematic to make
any statements on sensitivity and specificity in the
absence of a clinically relevant gold standard, a situa-
tion made more challenging in the case of moulds due
largely to the lack of investigations on the quality of
test extracts. Recent Finnish studies on occupational
mould exposure show that provocation testing with
commercial mould extracts may be significantly more
sensitive compared with the detection of sensitization
[230]. These data require validation. It is therefore
challenging to assess provocation reactions in mould
provocation tests, partly since often isolated delayed
reactions are described [230].
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4. Diagnostic work-up for infections
The reader is referred to the relevant guideline for de-
tails on the procedure in mould infections (systemic
mycoses).
5. Toxicological diagnostics
There are currently no practicable and validated test
methods that could be applied in clinical diagnostic
practice.
6. Unconventional diagnostic methods
Due to a lack of evidence, unconventional (or uncon-
ventionally used) diagnostic methods [231–233] are
not advised.
Treatment
Even if no causal link can be established between
symptoms/findings/disorders and the occurrence of
indoor mould/dampness, the first “therapeutic” mea-
sure to be undertaken from a preventive and hygienic
perspective in the case of dampness/mould damage
is prompt appropriate and professional remediation;
moreover, in the case of severe clinical pictures associ-
ated with high risk (immune suppression according to
KRINKO criteria [11], cystic fibrosis [mucoviscidosis],
asthma), immediate minimization of exposure needs
to be achieved.
General drug treatment
In principle, topical and/or systemic treatment is in-
dicated in mould allergy depending on the organ-spe-
cific manifestation of the allergic disorder.
The reader is referred to the relevant guidelines for
more details on (organ-specific) drug treatment of al-
lergies.
Specific immunotherapy (hyposensitization)
Specific immunotherapy (SIT) using mould extracts
should be applied as early in the disease course as
possible, particularly if drug treatment and avoidance
have previously failed to stabilize symptoms [234].
The relevant mould allergens need to be unequivo-
cally confirmed at diagnosis as the trigger of allergic
symptoms. The prerequisite for SIT is evidence of clin-
ically relevant allergen-specific IgE sensitization. The
combination of different test methods, together with
medical history, provides an adequate basis for SIT.
Hyposensitization presupposes a confirmed diagno-
sis. In this regard, the reader is referred to the current
guideline [235].
According to current data, only a handful of stud-
ies support the efficacy of SCIT in the outdoor-rel-
evant moulds Alternaria alternata and Cladosporium
herbarum [236, 237].
There is insufficient scientific evidence to date
to support the efficacy of sublingual immunother-
apy (SLIT) in terms of hyposensitization to indoor-
relevant moulds.
Exposure avoidance
As with all allergic diseases, exposure avoidance (aller-
gen avoidance) takes priority. Nevertheless, prompt
medication is required in order that a symptom-free
period is not followed by full-blown allergic disease.
It is of paramount importance to eliminate the causes
of the dampness creating a basis for indoor mould
growth. The AWMF mould guideline [1] provides
recommendations for indoors, outdoor air and foods
(recommendations without evidence).
Unconventional treatment methods
As with all medical procedures, unconventional treat-
ment procedures [231–233] need to be tested and eval-
uated according to current scientific knowledge and
will only be reimbursed by health insurers if the ther-
apeutic benefit is proven.
Remediation of living areas (buildings) affected by
dampness and mould growth
Proper remediation of dampness/mould damage in-
cludes the elimination of structural cause(s), the dry-
ing out and removal of all mould-infested materials as
well as subsequent fine cleaning. Details of these pro-
cedures do not form part of this guideline. More de-
tailed information can be found in the relevant mould
guidelines [2, 3, 5], as well as the revised version of the
UBA guideline (due to be published 2017).
Social status and dampness/mould infestation
Statistical surveys show that dampness/mould dam-
age is more frequently reported in homes of individ-
uals with low social status compared with the gen-
eral population (e. g. German Federal Statistical Of-
fice, 2006). This gives rise to particular problems for
low-social-status individuals in terms of the likelihood
of dampness/mould damage and its remediation [1].
Prevention
It is important, as a first step, to provide suscepti-
ble and immunosuppressed patients with information
on the risks associated with indoor mould exposure
and preventive measures [238, 239], possibly supple-
mented by home visits to inspect for Aspergillus fu-
migatus and Aspergillus flavus (only rarely found in-
doors) [240].
Prevention and exposure avoidance are paramount
in all cases of health-related disorders associated with
exposure to environmental factors. This applies in
particular to moulds. To ensure allergy prevention, it
is essential to avoid an indoor climate that promotes
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mould growth (high air humidity, lack of ventilation)
[241].
Further information can be found in the UBA
guideline on mould [2], as well as the revised version
of the UBA guideline (due to be published 2017).
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